



Results of Annual General Meeting

Sydney, 17 November 2022: Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolutions were passed and decided by way of poll.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its clinical drug candidate Veyonda[®], plus two innovative technology platforms – Chroma[™] (oncology) and Sofra[™] (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Mr David Franks, Company Secretary of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Disclosure of Proxy Votes

NOXOPHARM LIMITED

Annual General Meeting

Thursday, 17 November 2022



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	44,035,437	41,587,286 94.44%	1,204,683 2.74%	1,538,307	1,243,468 2.82%	49,823,991 94.67%	2,804,683 5.33%	1,555,807
2 Re-election of Mr Boris Patkin as Director	P	85,495,744	82,489,266 96.48%	2,566,560 3.00%	1,475,757	439,918 0.51%	89,939,921 95.57%	4,166,560 4.43%	1,475,757
3 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	85,440,126	82,064,282 96.05%	2,941,376 3.44%	1,531,375	434,468 0.51%	91,109,487 96.87%	2,941,376 3.13%	1,531,375
4 Adoption of the Employee Incentive Plan	P	43,280,719	39,406,988 91.05%	3,440,263 7.95%	37,442,131	433,468 1.00%	47,584,988 93.23%	3,457,763 6.77%	38,290,836
5 Approval of Issue of Incentive Securities to Dr Gisela Mautner, Managing Director and CEO of the Company	P	44,071,819	38,171,766 86.61%	5,485,135 12.45%	36,651,031	414,918 0.94%	47,179,921 89.58%	5,485,135 10.42%	36,668,531
6 Amendments to the Company's Constitution	P	85,401,894	81,835,202 95.82%	2,322,224 2.72%	1,569,607	1,244,468 1.46%	90,824,202 97.51%	2,322,224 2.49%	2,435,812
7 Renewal of Proportional Takeover Provisions	P	85,410,076	83,963,932 98.31%	200,819 0.24%	1,561,425	1,245,325 1.46%	92,971,289 99.78%	200,819 0.22%	2,410,130

